Jennifer L Cross

Title: **Jennifer L. Cross: Innovator in Hepatitis B Research**

Introduction

Jennifer L. Cross, based in Delta, CA, is a pioneering inventor known for her contributions to the field of virology. With a focus on innovative treatments for hepatitis B virus infections, she has made significant strides in medical science through her research and invention.

Latest Patents

Jennifer holds a patent titled "Compositions and methods for silencing hepatitis B virus gene expression." This groundbreaking invention provides compositions that include therapeutic nucleic acids, such as siRNA, designed to target and silence the gene expression of the Hepatitis B virus (HBV). The patent also details lipid particles containing these therapeutic nucleic acids and outlines methods for delivering these particles, enhancing treatment options for HBV and hepatitis D virus (HDV) infections in humans.

Career Highlights

Currently, Jennifer is an innovator at Arbutus Biopharma Corporation, where she applies her expertise to further research and develop therapies aimed at combating viral infections. Her work contributes directly to the advancement of medical treatments that can improve the quality of life for patients affected by HBV.

Collaborations

Throughout her career, Jennifer has collaborated with talented professionals in her field, including Ammen P. Dhillon and Amy C. H. Lee. These partnerships have helped drive innovation and research excellence in developing new antiviral therapies.

Conclusion

Jennifer L. Cross stands out as a significant figure in the domain of hepatitis B research. Her patent and ongoing work at Arbutus Biopharma Corporation underscore her commitment to finding effective solutions for viral infections. Through her contributions, she continues to inspire fellow researchers and pave the way for future innovations in medical science.